AlloVir's RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential

B of A Securities analyst Jason Zemansky initiated coverage on AlloVir Inc ALVR with a Buy rating and announced a price target of $17.

AlloVir is a clinical-stage biotech advancing cell therapies for prevention/ treatment of viruses in immunocompromised patients.

Supported by solid phase 2 proof-of-concept data and given high unmet need, the analyst thinks lead asset posoleucel has compelling and underappreciated upside with three ongoing pivotal studies capable of driving a near-term re-rating.

In the analyst's view, pricing remains a key overhang to the story, given the lack of clarity over posoleucel's ultimate indication.

Given clear economic support for posoleucel's use, with increasing openness among payers to reimburse cell-therapies, the analyst sees a compelling business case.

AlloVir sees potential for posoleucel beyond transplant patients, though the analyst thinks few on the Street see much upside here. 

The analyst added that ALVR106, AlloVir's early-stage candidate targeting four respiratory viruses should have broader utility beyond transplant with potential for greater upside.

Overall, the analyst sees a significant upside to the shares at current levels.

Price Action: ALVR shares are trading higher by 13.81% at $2.81 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorEquitiesNewsPenny StocksPrice TargetInitiationSmall CapMarketsAnalyst RatingsTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!